Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Income (2019 - 2025)

BridgeBio Pharma's Net Income history spans 7 years, with the latest figure at -$194.6 million for Q4 2025.

  • On a quarterly basis, Net Income rose 27.21% to -$194.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$704.5 million, a 33.87% decrease, with the full-year FY2025 number at -$732.9 million, down 34.89% from a year prior.
  • Net Income hit -$194.6 million in Q4 2025 for BridgeBio Pharma, down from -$185.0 million in the prior quarter.
  • Over the last five years, Net Income for BBIO hit a ceiling of -$19.1 million in Q1 2024 and a floor of -$267.4 million in Q4 2024.
  • Historically, Net Income has averaged -$155.4 million across 5 years, with a median of -$163.2 million in 2023.
  • Biggest five-year swings in Net Income: surged 86.59% in 2024 and later tumbled 640.71% in 2025.
  • Tracing BBIO's Net Income over 5 years: stood at -$180.6 million in 2021, then rose by 19.62% to -$145.1 million in 2022, then plummeted by 32.37% to -$192.1 million in 2023, then tumbled by 39.19% to -$267.4 million in 2024, then grew by 27.21% to -$194.6 million in 2025.
  • Business Quant data shows Net Income for BBIO at -$194.6 million in Q4 2025, -$185.0 million in Q3 2025, and -$183.8 million in Q2 2025.